Medicine (RMH) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 3 of 3
  • Item
    Thumbnail Image
    Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
    Davis, JE ; Sharpe, C ; Mason, K ; Tam, CS ; Koldej, RM ; Ritchie, DS (BMC, 2021-11-22)
    BACKGROUND: The development of Bruton's tyrosine kinase inhibitors (BTKi) for the treatment of chronic lymphocytic leukaemia (CLL) has provided a highly effective and relatively non-toxic alternative to conventional chemotherapy. Some studies have shown that BTKi can also lead to improvements in T cell immunity in patients despite in vitro analyses suggesting an immunosuppressive effect of BTKi on T cell function. METHODS: In this study, we examined both the in vitro effect and long-term in vivo effect of two clinically available BTKi, ibrutinib and zanubrutinib. Additional in vitro assessments were undertaken for a third BTKi, acalabrutinib. Immune subset phenotyping, cytokine secretion, T cell degranulation and proliferation assays were performed on peripheral blood mononuclear cells isolated from untreated CLL patients, and CLL patients on long-term (> 12 months) BTKi treatment. RESULTS: Similar to prior studies we observed that long-term BTKi treatment normalises lymphocyte subset frequency and reduces PD-1 expression on T cells. We also observed that T cells from patients taken prior to BTKi therapy showed an abnormal hyper-proliferation pattern typical of senescent T cells, which was normalised by long-term BTKi treatment. Furthermore, BTKi therapy resulted in reduced expression of the T cell exhaustion markers PD-1, TIM3 and LAG3 in late generations of T cells undergoing proliferation. CONCLUSIONS: Collectively, these findings indicate that there are critical differences between the in vitro effects of BTKi on T cell function and the effects derived from long-term BTKi exposure in vivo. Overall long-term exposure to BTKi, and particularly ibrutinib, resulted in improved T cell fitness in part due to suppressing the abnormal hyper-proliferation of CLL T cells and the associated development of T cell senescence.
  • Item
    No Preview Available
    Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study
    Barge, L ; Tran, S ; Kennedy, G ; Ritchie, DS ; Gottlieb, D ; Milliken, S ; Spencer, A ; Purtill, D ; Perera, T ; Doocey, RT ; Larsen, S ; Butler, A ; Bardy, P ; Greenwood, M ; Durrant, S ; Curley, C ; Stewart, C ; Tam, CS ; Collins, J ; Balendran, S ; Di Ciaccio, PR ; Patil, S ; Han, M-H ; Hamad, N (Elsevier BV, 2021-03)
  • Item
    No Preview Available
    T-Cell Replete Allogeneic Stem Cell Transplant Is an Effective Treatment Option for Patients with TP53 mutated Mantle Cell Lymphoma
    Scheffer Cliff, ER ; Lew, TE ; Blombery, P ; Dickinson, M ; Tam, CS ; Seymour, JF ; Bajel, A ; Ritchie, DS ; Khot, A (Elsevier BV, 2021-03)